The cholinergic synapse operates through a tightly regulated sequence: acetylcholine (ACh) is synthesized in the nerve terminal, packaged into synaptic vesicles, released by calcium-dependent exocytosis, and then rapidly hydrolyzed in the synaptic cleft. Each step in this cycle represents a potential pharmacological target, and understanding the molecular machinery at each step is prerequisite to understanding how drugs that act at this synapse produce their clinical effects.
Choline Uptake. The rate-limiting step in ACh synthesis is not the synthetic enzyme itself but the availability of its substrate, choline. Free choline is not synthesized de novo in the nerve terminal at rates sufficient to sustain high-frequency cholinergic firing; instead, choline is actively transported from the synaptic cleft and extracellular fluid into the presynaptic terminal by the high-affinity choline transporter (CHT1), encoded by the solute carrier family 5 member 7 gene. CHT1 is a sodium-dependent, hemicholinium-3-sensitive transporter located on the presynaptic plasma membrane. Its transport capacity is tightly coupled to neuronal activity: vesicular fusion events during exocytosis insert additional CHT1 molecules into the plasma membrane, creating a demand-driven mechanism that increases choline uptake precisely when firing rates are high and choline demand is greatest. Hemicholinium-3, a research pharmacological tool, competitively inhibits CHT1 and causes progressive depletion of ACh stores as firing continues without choline replenishment, ultimately producing a presynaptic blockade of neuromuscular transmission.1
Acetylcholine Synthesis. Within the nerve terminal cytoplasm, choline acetyltransferase (ChAT) catalyzes the transfer of an acetyl group from acetyl-coenzyme A (acetyl-CoA) to choline, producing ACh and free coenzyme A (CoA). ChAT is constitutively expressed in all cholinergic neurons and is both a marker of cholinergic phenotype and a quantitative index of cholinergic terminal density in tissue studies. Acetyl-CoA used for ACh synthesis is derived from mitochondrial pyruvate oxidation; accordingly, conditions that impair mitochondrial function or glucose supply can reduce ACh synthetic capacity in cholinergic terminals. In Alzheimer's disease (AD), the loss of basal forebrain cholinergic neurons is reflected in substantial reductions in cortical and hippocampal ChAT activity, providing the mechanistic rationale for the acetylcholinesterase (AChE) inhibitor approach to symptomatic treatment.2
Vesicular Storage. Newly synthesized ACh is not stored free in the cytoplasm but is rapidly transported into synaptic vesicles by the vesicular acetylcholine transporter (VAChT). VAChT operates as an antiporter, exchanging two intravesicular protons for one cytoplasmic ACh molecule, with the driving force provided by the proton electrochemical gradient generated by a vacuolar-type H+-ATPase on the vesicular membrane. Each small synaptic vesicle contains approximately 5,000 to 10,000 ACh molecules; this discrete unit of transmitter is termed a quantum, and quantal release forms the basis of miniature end-plate potential (MEPP) physiology. Vesamicol is a pharmacological agent that blocks VAChT and thereby prevents vesicular ACh loading; like hemicholinium-3, it is primarily a research tool. The density of VAChT expression determines the quantal content of vesicles and is regulated by neuronal activity, providing a second level at which presynaptic cholinergic output can be modulated.1
Calcium-Dependent Exocytosis and the SNARE Complex. The SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) complex mediates vesicle fusion with the presynaptic membrane during ACh release. Action potential propagation into the presynaptic terminal depolarizes the membrane and opens voltage-gated calcium channels (predominantly P/Q-type at the neuromuscular junction [NMJ], N-type at autonomic synapses). The resulting influx of calcium ions triggers vesicle fusion through assembly of the SNARE complex, consisting of VAMP (vesicle-associated membrane protein, also called synaptobrevin) on the vesicle and syntaxin-1 plus SNAP-25 (synaptosomal-associated protein of 25 kDa) on the target membrane. Calcium binding to synaptotagmin-1 on the vesicle membrane acts as the calcium sensor that triggers rapid SNARE zippering and membrane fusion. Botulinum toxins (serotypes A through G) produced by Clostridium botulinum are zinc-dependent endoproteases that cleave specific SNARE proteins: serotypes A and E cleave SNAP-25, serotypes B, D, F, and G cleave VAMP/synaptobrevin, and serotype C cleaves both syntaxin and SNAP-25. Cleavage of any SNARE component prevents vesicle fusion and abolishes ACh release, producing the characteristic flaccid paralysis of botulism. The same mechanism underlies the therapeutic applications of botulinum toxin A in focal dystonia, spasticity, hyperhidrosis (excessive sweating), and overactive bladder.3
Presynaptic Autoreceptors. Released ACh feeds back onto presynaptic muscarinic M2 (subtype 2) autoreceptors located on the cholinergic nerve terminal itself. Activation of these Gi-coupled receptors inhibits adenylyl cyclase, reduces calcium channel opening, and suppresses further ACh release, providing a negative feedback mechanism that prevents excessive cholinergic activation during sustained high-frequency firing. This presynaptic M2 autoreceptor mechanism has pharmacological implications: muscarinic agonists can reduce their own physiological response by activating presynaptic autoreceptors that diminish further ACh release, while M2-selective antagonists can paradoxically enhance cholinergic transmission by removing this autoinhibition. At ganglionic synapses and in the central nervous system (CNS), presynaptic nicotinic receptors also modulate ACh release through positive feedback mechanisms.4
Hemicholinium-3: blocks CHT1 (high-affinity choline transporter), depletes ACh by limiting choline availability. Vesamicol: blocks VAChT (vesicular ACh transporter), prevents vesicular loading. Botulinum toxin: cleaves SNARE proteins (VAMP, SNAP-25, or syntaxin depending on serotype), prevents exocytosis. All three produce presynaptic cholinergic blockade by distinct mechanisms upstream of receptor activation. Clinical relevance: botulinum toxin A used therapeutically; botulism and organophosphate poisoning arise from opposite ends of cholinergic dysregulation.
Termination of ACh signaling in the synaptic cleft is accomplished not by reuptake (as with catecholamines and serotonin) but by enzymatic hydrolysis. The speed of this hydrolysis is extraordinary: acetylcholinesterase (AChE) hydrolyzes ACh at a catalytic rate approaching the diffusion limit, with each enzyme molecule capable of processing approximately 25,000 ACh molecules per second. This kinetic efficiency means that the duration of cholinergic signaling is determined almost entirely by AChE activity, making AChE inhibition a powerful and pharmacologically versatile strategy.
Mechanism of ACh Hydrolysis by AChE. AChE belongs to the serine hydrolase superfamily. Its active site consists of two functionally distinct subsites: the esteratic (catalytic) site, containing the catalytic triad of serine-200, histidine-440, and glutamate-327, and the anionic site (also called the choline-binding site), which accommodates the quaternary ammonium group of ACh through electrostatic and hydrophobic interactions. Hydrolysis proceeds in two steps: ACh binds to the active site with the carbonyl carbon positioned adjacent to the serine hydroxyl; nucleophilic attack by the serine oxygen produces a tetrahedral intermediate that collapses to yield choline (released into the cleft) and an acetylated enzyme intermediate (acetyl-serine); rapid hydrolysis of the acetyl-enzyme intermediate by water then regenerates the free enzyme and releases acetate. The entire catalytic cycle takes approximately 40 microseconds. AChE is anchored at the NMJ (neuromuscular junction) as a globular tetramer attached to the synaptic basal lamina via the collagen-like tail subunit ColQ, ensuring the enzyme is precisely positioned at the site of ACh release.5
Tissue Distribution of AChE. AChE is expressed at all cholinergic synapses: the NMJ, autonomic ganglia, postganglionic parasympathetic neuroeffector junctions, and throughout the central nervous system (CNS) at cholinergic terminals. In the CNS, AChE is particularly concentrated in the caudate nucleus, hippocampus, and cerebral cortex, regions that receive dense cholinergic innervation from the basal forebrain (nucleus basalis of Meynert) and brainstem (pedunculopontine nucleus). Red blood cells (erythrocytes) express AChE on their external surface (erythrocyte AChE, or G1 form) and plasma AChE activity measurements using erythrocyte AChE are used clinically to assess organophosphate (OP) exposure severity, because erythrocyte AChE activity is inhibited in parallel with synaptic AChE during OP poisoning. This measurement provides a surrogate index of synaptic AChE inhibition in tissues that are inaccessible to direct measurement.6
Butyrylcholinesterase. Butyrylcholinesterase (BuChE), also called pseudocholinesterase or plasma cholinesterase, is a serine hydrolase structurally related to AChE but with distinct tissue distribution, substrate specificity, and pharmacological significance. BuChE is synthesized primarily in the liver and is present at high concentrations in plasma, liver, intestinal mucosa, and glial cells. Unlike AChE, which preferentially hydrolyzes ACh, BuChE has broader substrate specificity and hydrolyzes a range of choline esters and non-choline ester substrates including butyrylcholine, propionylcholine, and of particular clinical relevance, succinylcholine and mivacurium (both depolarizing and some short-acting non-depolarizing neuromuscular blocking agents [NMBAs]). The physiological role of BuChE is uncertain; it may serve as a backup for AChE in hydrolyzing ACh under conditions of high cholinergic activity, and it may play a role in detoxifying ester-containing xenobiotics. Genetic variants that reduce BuChE activity (most commonly the dibucaine-resistant variant, E1u, with a prevalence of approximately 1 in 3,500 individuals for the homozygous form) cause prolonged neuromuscular blockade after succinylcholine administration, a pharmacogenomic consideration relevant to anesthesia practice.7
Pharmacological Significance of AChE vs. BuChE Selectivity. The distinction between AChE and BuChE selectivity has therapeutic relevance for AChE inhibitors used in Alzheimer's disease treatment. Donepezil and galantamine are relatively selective for AChE over BuChE. Rivastigmine inhibits both AChE and BuChE with roughly equal potency, which has been proposed as an advantage in Alzheimer's disease because BuChE expression in the brain increases as AChE expression declines with disease progression, potentially making BuChE inhibition increasingly relevant in advanced stages. However, the clinical superiority of dual inhibition over selective AChE inhibition has not been definitively established. For organophosphate toxicology, both AChE and BuChE are inhibited by OP compounds, and plasma BuChE activity serves as an accessible surrogate marker for systemic OP exposure because it is more easily measured than synaptic AChE activity. BuChE activity is typically inhibited before clinical symptoms appear, making it a potentially useful early biomarker of exposure in occupational and forensic contexts.67
AChE: primary synaptic enzyme; located at NMJ, ganglia, CNS; measured via erythrocyte AChE in OP poisoning; inhibited by neostigmine, physostigmine, organophosphates. BuChE: plasma/liver enzyme; hydrolyzes succinylcholine and mivacurium; genetic variants cause prolonged NMB; inhibited by rivastigmine (dual inhibitor) and organophosphates; BuChE activity depressed before symptoms in OP exposure. Donepezil and galantamine: AChE-selective. Rivastigmine: dual AChE + BuChE inhibitor.
Muscarinic receptors are G-protein-coupled receptors (GPCRs) that mediate the effects of ACh at parasympathetic neuroeffector junctions, in autonomic ganglia, and throughout the central nervous system (CNS). Five subtypes have been identified (M1 through M5), each encoded by a distinct gene, each with a characteristic tissue distribution, G-protein coupling partner, and downstream effector profile. The clinical pharmacology of muscarinic agonists and antagonists is largely determined by which subtypes are engaged at therapeutic concentrations and in which tissues those subtypes are expressed.
M1 Receptors. M1 receptors are Gq-coupled receptors expressed predominantly in the cerebral cortex, hippocampus, striatum, and autonomic ganglia. Gq coupling activates phospholipase C-beta (PLC-beta), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC), together producing excitatory cellular responses. At autonomic ganglia, M1 receptors mediate a slow excitatory postsynaptic potential (slow EPSP) that modulates ganglionic transmission by depolarizing the ganglionic neuron and enhancing its responsiveness to nicotinic receptor-mediated fast EPSPs. In the CNS, M1 receptor activation in the cortex and hippocampus facilitates cognitive processes including learning and memory consolidation, which is why M1-selective agonists have been investigated as pro-cognitive agents in Alzheimer's disease, and why muscarinic antagonists with CNS penetration produce cognitive impairment as a dose-dependent adverse effect.4
M2 Receptors. M2 (muscarinic subtype 2) receptors are Gi/o-coupled receptors and represent the dominant muscarinic subtype in the heart, where they are expressed in the sinoatrial (SA) node, atrioventricular (AV) node, and atrial myocardium. Gi coupling inhibits adenylyl cyclase, reducing cyclic adenosine monophosphate (cAMP) production and thereby decreasing the activity of cAMP-dependent protein kinase A (PKA). In addition, M2 receptor activation releases the Gi beta-gamma subunit, which directly activates inwardly rectifying potassium channels (IKACh, GIRK channels), hyperpolarizing the SA node pacemaker cells and slowing the rate of spontaneous diastolic depolarization. The resulting decrease in heart rate (negative chronotropy) is the primary cardiac effect of vagal tone. M2 receptors also mediate negative dromotropy (slowing of AV node conduction) and, to a lesser degree, negative inotropy in the atria. In the CNS, M2 receptors serve as presynaptic autoreceptors on cholinergic terminals (as described in Section 1) and are also found on non-cholinergic neurons where they modulate neurotransmitter release through Gi-mediated suppression of calcium influx.48
M3 Receptors. M3 (muscarinic subtype 3) receptors are Gq-coupled and are the principal muscarinic subtype mediating smooth muscle contraction and glandular secretion. In the gastrointestinal (GI) tract, M3 receptor activation contracts intestinal smooth muscle, increases peristaltic activity, and augments gastric acid secretion. In the urinary bladder detrusor muscle, M3 activation produces bladder contraction and is the primary pharmacological target for overactive bladder therapy, where M3-selective antagonists (darifenacin, solifenacin) are used to reduce detrusor overactivity. In the airways, M3 receptor activation contracts bronchial smooth muscle (bronchoconstriction) and stimulates mucus secretion; bronchodilatory muscarinic antagonists (ipratropium, tiotropium) act predominantly at M3 receptors in airway smooth muscle to reverse parasympathetic bronchoconstriction. In exocrine glands (salivary glands, lacrimal glands, sweat glands, pancreatic acini), M3 receptors mediate secretion through Gq-IP3-calcium signaling. In vascular endothelium, M3 receptors stimulate nitric oxide (NO) synthesis via endothelial nitric oxide synthase (eNOS), producing indirect vasodilation; this response is endothelium-dependent and is absent in diseased or denuded vessels.4
M4 Receptors. M4 (muscarinic subtype 4) receptors are Gi/o-coupled and are expressed predominantly in the CNS, with particularly high density in the striatum (caudate nucleus and putamen), where they are found on dopaminergic terminals and GABAergic medium spiny neurons. M4 receptor activation inhibits adenylyl cyclase and modulates dopamine release and dopaminergic signaling in the striatum, establishing a cholinergic-dopaminergic interaction that is relevant to movement disorders. In Parkinson's disease (PD), the loss of nigral dopaminergic input to the striatum unmasks relative cholinergic overactivity mediated in part through M4 receptors, providing the rationale for the historical use of muscarinic antagonists (benztropine, trihexyphenidyl) as antiparkinsonian agents. M4-selective positive allosteric modulators have been investigated as antipsychotic agents, exploiting the modulatory role of striatal M4 receptors in dopaminergic circuits implicated in psychosis. M4 receptors also contribute to the regulation of pain processing in the spinal cord.4
M5 Receptors. M5 receptors are Gq-coupled and represent the least well-characterized muscarinic subtype. They are expressed in the CNS, predominantly in the substantia nigra, ventral tegmental area (VTA), and hippocampus, and are the only muscarinic receptor subtype expressed in the brain vasculature, where they mediate ACh-induced cerebrovascular dilation. M5 receptors in the VTA and nucleus accumbens have been implicated in the modulation of dopamine release in reward pathways, and preclinical studies suggest M5 receptor antagonism may attenuate opioid and psychostimulant reward, making M5 a potential target for addiction pharmacotherapy. There are no clinically approved drugs that act selectively at M5 receptors.4
M1 (Gq): cortex, hippocampus, ganglia — cognition, slow EPSP. M2 (Gi): SA node, AV node, atria, presynaptic autoreceptor — bradycardia, AV slowing, autoinhibition. M3 (Gq): GI smooth muscle, bladder detrusor, bronchial smooth muscle, exocrine glands, vascular endothelium — contraction, secretion, vasodilation. M4 (Gi): striatum — dopamine modulation, movement. M5 (Gq): VTA, cerebrovascular — reward, cerebral blood flow. Drug selectivity: darifenacin/solifenacin target M3 (bladder); ipratropium/tiotropium target M3 (airways); benztropine targets M1/M4 (CNS); atropine is non-selective.
Nicotinic ACh receptors (nAChRs) are pentameric ligand-gated ion channels that mediate fast excitatory synaptic transmission at the neuromuscular junction, autonomic ganglia, and throughout the central nervous system (CNS). Unlike muscarinic receptors, which signal through G-protein intermediaries over hundreds of milliseconds, nicotinic receptor activation produces ion channel opening within microseconds of ACh binding, making nicotinic transmission inherently fast and suited to situations demanding rapid, precisely timed responses. The two principal pharmacological subtypes, muscle-type (N-M) and neuronal-type (N-N), differ in subunit composition, anatomical distribution, and sensitivity to blocking agents in ways that are clinically exploited.
Structural Architecture of nAChRs. All nAChRs are pentamers assembled from homologous subunit proteins. Each subunit has four transmembrane domains (TM1 through TM4), with the TM2 (second transmembrane) domain from each of the five subunits lining the central ion-conducting pore. When two ACh molecules bind simultaneously to the extracellular ligand-binding domain (one per binding site, located at the interface between adjacent subunits), the receptor undergoes a conformational change that opens the pore to cation influx: primarily sodium and potassium flow along their electrochemical gradients, with a smaller but physiologically significant contribution of calcium influx. The net inward cation flow depolarizes the postsynaptic membrane. Receptor activation is followed by rapid desensitization, during which the receptor transitions to a closed, agonist-bound state that is refractory to further activation. Prolonged or repeated agonist exposure accelerates desensitization, a mechanism exploited by succinylcholine's depolarizing block at the NMJ (neuromuscular junction).9
Muscle-Type Nicotinic Receptors (N-M). The muscle-type nAChR at the mature NMJ is composed of two alpha-1 (alpha1) subunits, one beta-1 (beta1) subunit, one delta subunit, and one epsilon subunit (alpha12beta1-delta-epsilon stoichiometry in adults; the epsilon subunit replaces a gamma subunit present in the fetal and denervated forms). The two ACh binding sites are located at the alpha1-delta and alpha1-epsilon subunit interfaces. This subunit composition confers specific pharmacological properties: the N-M receptor is selectively blocked by tubocurarine, pancuronium, and other non-depolarizing neuromuscular blocking agents (NDNMBAs), is activated and then desensitized by succinylcholine, and is insensitive to ganglionic blocking doses of trimethaphan or hexamethonium. The high density of N-M receptors at the NMJ endplate region (approximately 10,000 receptors per square micrometer) and the large quantal content of motor nerve terminals provide a substantial safety margin: approximately 70 to 80 percent of receptors must be blocked before neuromuscular transmission fails, a consideration in the management of myasthenia gravis (MG) and in titrating neuromuscular blockade in anesthesia.910
Ganglionic Nicotinic Receptors (N-N). Neuronal nicotinic receptors at autonomic ganglia are composed predominantly of alpha3 and beta4 subunits (alpha3-beta4 pentamers), with contributions from alpha5 subunits in some ganglia. The alpha3-beta4 composition confers pharmacological properties distinct from the muscle-type receptor: N-N receptors are selectively blocked by hexamethonium and trimethaphan at concentrations that do not block N-M receptors, are not blocked by non-depolarizing NMBAs at clinical doses, and are relatively insensitive to alpha-bungarotoxin (which blocks N-M receptors with high affinity). Ganglionic blockade by hexamethonium or trimethaphan produces profound autonomic blockade affecting both sympathetic and parasympathetic ganglia simultaneously, resulting in orthostatic hypotension, tachycardia (loss of vagal tone), mydriasis (loss of pupilloconstrictor tone), dry mouth, urinary retention, and ileus. The inability to selectively block one division of the autonomic nervous system was the principal reason ganglionic blockers were displaced by more selective antihypertensive agents.10
CNS Nicotinic Receptors. The CNS contains a diverse array of nAChR subtypes assembled from combinations of alpha2 through alpha10 and beta2 through beta4 subunits. The most abundant CNS nAChR subtype is the alpha4-beta2 heteromeric receptor, which constitutes approximately 90 percent of high-affinity nicotine binding sites in the brain and is the primary receptor mediating nicotine addiction. Alpha4-beta2 receptors are located presynaptically on dopaminergic terminals in the nucleus accumbens and on GABAergic and glutamatergic neurons throughout the CNS; their activation by nicotine enhances dopamine release in reward pathways, explaining nicotine's reinforcing properties. Varenicline, the smoking cessation pharmacotherapy, acts as a partial agonist at alpha4-beta2 receptors, providing partial activation (reducing craving and withdrawal) while competitively blocking the full agonist response to nicotine. Homomeric alpha7 receptors, another major CNS subtype, have high calcium permeability and are concentrated at presynaptic terminals throughout the cortex and hippocampus, where they modulate glutamate and GABA (gamma-aminobutyric acid) release. Alpha7 receptors desensitize extremely rapidly and have been investigated as targets for cognitive enhancement in schizophrenia and Alzheimer's disease.11
N-M (alpha12beta1-delta-epsilon at mature NMJ): blocked by non-depolarizing NMBAs (tubocurarine, rocuronium); depolarized then blocked by succinylcholine; high-affinity alpha-bungarotoxin binding; 70–80% occupancy threshold before transmission fails. N-N (alpha3-beta4 at ganglia): blocked by hexamethonium, trimethaphan; not blocked by clinical NDNMBA doses; blockade produces combined sympathetic + parasympathetic failure. CNS alpha4-beta2: site of nicotine addiction and varenicline action. CNS alpha7: high calcium permeability; target for cognitive pharmacology research.
The autonomic nervous system maintains physiological homeostasis through the continuous interplay of sympathetic and parasympathetic tone. At most organs, resting autonomic tone reflects a balance between these two divisions, but at specific targets the parasympathetic (cholinergic) division dominates under basal conditions. Understanding which organs are under predominant cholinergic control at rest, and what happens when that control is either excessively enhanced or pharmacologically withdrawn, is the foundation for predicting the clinical effects of every drug in this chapter.
Organs Under Dominant Parasympathetic Tone at Rest. The heart is the most clinically consequential organ under dominant parasympathetic tone at rest. Vagal tone continuously slows the intrinsic sinoatrial (SA) node firing rate: the denervated heart (as in cardiac transplantation) beats at approximately 100 to 110 beats per minute, while the innervated heart at rest beats at 60 to 80 beats per minute, reflecting the net effect of resting vagal tone. Atropine administration to a resting adult increases heart rate toward the intrinsically denervated rate by removing vagal M2 (muscarinic subtype 2)-mediated slowing. The gastrointestinal (GI) tract is under dominant parasympathetic tone with respect to both motility and secretory function: basal GI motility, intestinal secretion, and gastric acid output are maintained by cholinergic drive through the vagus nerve and pelvic nerves acting on M3 (muscarinic subtype 3) receptors in the gut wall. The urinary bladder detrusor is also under resting cholinergic tone through the pelvic nerves, with M3 receptor activation maintaining basal detrusor contractility. The eye maintains pupillary constriction through continuous M3-mediated activation of the pupilloconstrictor (sphincter pupillae) muscle innervated via the ciliary ganglion, and accommodation (near focus) is maintained by ciliary muscle contraction through the same pathway.8
Consequences of Cholinergic Excess. Excessive cholinergic activity, whether from AChE inhibitor toxicity, muscarinic agonist overdose, or organophosphate (OP) poisoning, produces a predictable constellation of signs and symptoms arising from overstimulation of muscarinic and nicotinic receptors simultaneously. The muscarinic effects are summarized by the mnemonics SLUDGE (Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis) and DUMBELS (Defecation, Urination, Miosis, Bradycardia/Bronchospasm/Bronchorrhea, Emesis, Lacrimation, Salivation), reflecting the consequences of M3 and M2 receptor hyperstimulation across target organs. Simultaneously, nicotinic overstimulation at the NMJ (neuromuscular junction) produces an initial fasciculation phase followed by depolarizing block and flaccid paralysis; at autonomic ganglia, nicotinic overstimulation causes an initial sympathomimetic burst followed by ganglionic failure. Central nervous system (CNS) muscarinic and nicotinic receptor hyperstimulation produces anxiety, seizures, and loss of consciousness. The clinical severity of cholinergic excess correlates with the degree of AChE inhibition: greater than 50 percent inhibition typically produces mild symptoms, greater than 70 percent produces moderate toxicity, and greater than 90 percent inhibition is associated with life-threatening respiratory failure from the combination of bronchospasm, bronchorrhea, and neuromuscular paralysis of the diaphragm.12
Consequences of Cholinergic Deficit. Pharmacological muscarinic blockade produces the anticholinergic syndrome: tachycardia (loss of M2-mediated vagal slowing), mydriasis (loss of M3 pupilloconstrictor tone), cycloplegia (loss of ciliary muscle M3 tone, impairing near vision), dry mouth (loss of salivary gland M3 secretion), urinary retention (loss of detrusor M3 tone with maintenance of internal urethral sphincter sympathetic tone), constipation (loss of GI M3 motility), decreased sweating (loss of cholinergic eccrine sweat gland activation), flushing (cutaneous vasodilation), and in central nervous system (CNS)-penetrating agents, cognitive impairment, confusion, agitation, and delirium. The classic mnemonic is "hot as a hare, dry as a bone, red as a beet, blind as a bat, mad as a hatter," representing hyperthermia from anhidrosis (inability to sweat), dry mucous membranes and skin, cutaneous flushing, mydriasis with cycloplegia, and CNS toxicity respectively. Elderly patients and those with pre-existing cognitive impairment are at substantially greater risk of CNS anticholinergic toxicity at doses that would produce only peripheral effects in younger adults, a consideration that shapes prescribing for anticholinergic drugs across virtually every therapeutic category in Modules 02 and 04.8
Cholinergic Deficit in Disease. Beyond pharmacological interventions, cholinergic deficit is the neuropathological hallmark of Alzheimer's disease (AD). The cholinergic hypothesis of AD, formulated in the late 1970s and early 1980s based on the observation of selective loss of basal forebrain cholinergic neurons projecting to the cortex and hippocampus, provided the rationale for the AChE inhibitor class of AD therapeutics. While the cholinergic hypothesis does not fully account for the complexity of AD pathophysiology, the cholinergic deficit remains a pharmacologically addressable target and AChE inhibitors remain the mainstay of symptomatic therapy. In Parkinson's disease (PD), the relative excess of striatal cholinergic interneuron activity in the setting of dopaminergic denervation produces tremor and rigidity that respond to muscarinic antagonist therapy (benztropine, trihexyphenidyl), representing pharmacological restoration of cholinergic-dopaminergic balance in the striatum. In myasthenia gravis (MG), the target of the autoimmune attack is the N-M nicotinic receptor at the NMJ, reducing the safety margin of neuromuscular transmission and producing fatigable weakness that responds to AChE inhibitor therapy by prolonging the duration of ACh action at the reduced number of available receptors.10
Dominant parasympathetic tone at rest: heart (vagal slowing via M2), GI tract (motility + secretion via M3), bladder detrusor (contraction via M3), eye (miosis + accommodation via M3). Cholinergic excess: SLUDGE/DUMBELS (muscarinic) + fasciculations then flaccid paralysis (nicotinic NMJ) + seizures (CNS). Cholinergic deficit (anticholinergic syndrome): tachycardia, mydriasis, cycloplegia, dry mouth, urinary retention, constipation, anhidrosis, flushing, and CNS delirium in susceptible patients. Disease states: cholinergic deficit in AD (basal forebrain) and PD (striatal imbalance); NMJ receptor loss in MG. These patterns predict adverse effects for every drug class in Modules 02–04.
Ferguson SM, Blakely RD. The choline transporter resurfaces: new roles for synaptic vesicles? Mol Interv. 2004;4(1):22-37.
doi:10.1124/mi.4.1.22Mesulam MM. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show? Learn Mem. 2004;11(1):43-49.
doi:10.1101/lm.69204Montecucco C, Schiavo G. Structure and function of tetanus and botulinum neurotoxins. Q Rev Biophys. 1995;28(4):423-472.
doi:10.1017/s0033583500003292Wess J, Eglen RM, Gautam D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nat Rev Drug Discov. 2007;6(9):721-733.
doi:10.1038/nrd2379Dvir H, Silman I, Harel M, Rosenberry TL, Sussman JL. Acetylcholinesterase: from 3D structure to function. Chem Biol Interact. 2010;187(1-3):10-22.
doi:10.1016/j.cbi.2010.01.042Worek F, Wille T, Koller M, Thiermann H. Reactivation kinetics of a series of related bispyridinium oximes with organophosphate-inhibited human acetylcholinesterase — Structure-activity relationships. Biochem Pharmacol. 2012;83(12):1700-1706.
doi:10.1016/j.bcp.2012.03.002Lockridge O. Review of human butyrylcholinesterase structure, function, genetic variants, history of use in the clinic, and potential therapeutic uses. Pharmacol Ther. 2015;148:34-46.
doi:10.1016/j.pharmthera.2014.11.011Eglen RM. Muscarinic receptor subtypes in neuronal and non-neuronal cholinergic function. Auton Autacoid Pharmacol. 2006;26(3):219-233.
doi:10.1111/j.1474-8673.2006.00368.xTaly A, Corringer PJ, Guedin D, Lestage P, Changeux JP. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov. 2009;8(9):733-750.
doi:10.1038/nrd2927Sine SM. End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. Physiol Rev. 2012;92(3):1189-1234.
doi:10.1152/physrev.00015.2011Gotti C, Clementi F. Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol. 2004;74(6):363-396.
doi:10.1016/j.pneurobio.2004.09.006Eddleston M, Buckley NA, Eyer P, Dawson AH. Management of acute organophosphorus pesticide poisoning. Lancet. 2008;371(9612):597-607.
doi:10.1016/S0140-6736(07)61202-1